SLS — SELLAS Life Sciences Group, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1390478 ·
Last close
$8.12
Market Cap
$1.51B
52W High
$9.10
52W Low
$3.95
ADV30
7,632,868
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,252,000 | -8,407,000 | 114,177,000 | 107,097,000 | 6,765,000 |
| Dec 2025 | 0 | — | -8,255,000 | -7,658,000 | 78,345,000 | 71,793,000 | 7,474,000 |
| Sep 2025 | 0 | — | -7,083,000 | -6,791,000 | 51,555,000 | 44,320,000 | 5,925,000 |
| Jun 2025 | 0 | — | -6,873,000 | -6,601,000 | 32,305,000 | 25,297,000 | 6,156,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,389,000
Investing CF
$0
Financing CF
$86,296,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.30
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-274,988,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-28,274,000
Pretax Income TTM
$-26,863,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,274,000 | -26,863,000 | 78,345,000 | 7,474,000 | — | -28,389,000 |
| Dec 2024 | 0 | -31,513,000 | -30,881,000 | 19,432,000 | 9,967,000 | — | -35,402,000 |
| Dec 2023 | 0 | -37,869,000 | -37,340,000 | 6,219,000 | 14,195,000 | — | -31,410,000 |
| Dec 2022 | 1,000,000 | -31,950,000 | -41,301,000 | 20,943,000 | 16,092,000 | — | -23,809,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$16,690,000
NetIncome TTM
$-30,482,000
OpCashFlow TTM
$0
Assets (Latest)
$19,432,000
Forward EPS
$-0.15
Max Pain — expiry 2026-05-29
max pain strike: $6.50 · spot: $8.12 · call oi: 11,729 · put oi: 2,688
Expected Move to 2026-05-29:
±$1.18
(14.47%) —
implied range
$6.94 –
$9.29
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | $1.51B | $31.75 | — |
| PGEN | PRECIGEN, INC. | $1.51B | $4.24 | — |
| BHVN | Biohaven Ltd. | $1.52B | $10.07 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $1.52B | $13.68 | — |
| PRGO | PERRIGO Co plc | $1.49B | $10.80 | — |
News headlines (Yahoo Finance, 1h cache)
SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial Readout
2026-05-26 11:26 · Yahoo
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst
2026-05-22 03:54 · Yahoo
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS
2026-05-21 07:02 · Yahoo
Why Did ARM, SLS, EBAY Stocks Surge To 52-Week Highs?
2026-05-21 04:46 · Yahoo
SELLAS Life Sciences (SLS) Is Up 50.5% After Pivotal AML Trial Nears Readout And Adds Funding Flexibility – Has The Bull Case Changed?
2026-05-15 19:14 · Yahoo
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
2026-05-14 12:00 · Yahoo
High Growth Tech Stocks in US for May 2026
2026-05-14 11:38 · Yahoo
SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses
2026-05-13 14:18 · Yahoo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
2026-05-13 12:06 · Yahoo
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.